Clearly, further in-depth investigations including pharmacokinetic assessments are thus needed to fully evaluate the possibility of using different dynamin inhibitors to dampen tumor growth across various in vivo models of leukemia and lymphoma (see also [16]). This evidence concerns the gene DNM1 and lymphoma.